NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as BRISTOL MYERS SQUIBB. It is marketed under 1 brand name, including IDHIFA. Available in 2 different strengths, such as EQ 50MG BASE, EQ 100MG BASE, and administered through 1 route including TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"35516","ingredient":"ENASIDENIB MESYLATE","trade_name":"IDHIFA","family_id":"0f3d6dfca88c4bffb18e","publication_number":"US10610125B2","cleaned_patent_number":"10610125","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-06-21","publication_date":"2020-04-07","legal_status":"Granted"} | US10610125B2 | 07 Apr, 2020 | Granted | 21 Jun, 2030 | |
| {"application_id":"107421","ingredient":"ENASIDENIB MESYLATE","trade_name":"IDHIFA","family_id":"617c9909002042c9bebc","publication_number":"US10294215B2","cleaned_patent_number":"10294215","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-01-07","publication_date":"2019-05-21","legal_status":"Patented case"} | US10294215B2 Formulation | 21 May, 2019 | Patented case | 07 Jan, 2033 | |
| {"application_id":"42020","ingredient":"ENASIDENIB MESYLATE","trade_name":"IDHIFA","family_id":"617c9909002042c9bebc","publication_number":"US9512107B2","cleaned_patent_number":"9512107","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-01-07","publication_date":"2016-12-06","legal_status":"Patented case"} | US9512107B2 Molecular Formulation | 06 Dec, 2016 | Patented case | 07 Jan, 2033 | |
| {"application_id":"42073","ingredient":"ENASIDENIB MESYLATE","trade_name":"IDHIFA","family_id":"0d3d437d9a524ae09ff1","publication_number":"US10093654B2","cleaned_patent_number":"10093654","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-08-01","publication_date":"2018-10-09","legal_status":"Granted"} | US10093654B2 Molecular Formulation | 09 Oct, 2018 | Granted | 01 Aug, 2034 | |
| {"application_id":"42107","ingredient":"ENASIDENIB MESYLATE","trade_name":"IDHIFA","family_id":"0d3d437d9a524ae09ff1","publication_number":"US9738625B2","cleaned_patent_number":"9738625","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-08-01","publication_date":"2017-08-22","legal_status":"Granted"} | US9738625B2 Molecular | 22 Aug, 2017 | Granted | 01 Aug, 2034 | |
| {"application_id":"42067","ingredient":"ENASIDENIB MESYLATE","trade_name":"IDHIFA","family_id":"617c9909002042c9bebc","publication_number":"US9732062B2","cleaned_patent_number":"9732062","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-09-16","publication_date":"2017-08-15","legal_status":"Granted"} | US9732062B2 Molecular | 15 Aug, 2017 | Granted | 16 Sep, 2034 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Enasidenib Mesylate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.